Gaithersburg, Md., February 28, 2022 – miRecule, Inc. today announces it has won a joint Maryland Industrial Partnerships (MIPS) grant in collaboration with Dr. Robert Bloch at the University of Maryland, Baltimore for $100,000. This collaborative partnership is...
Gaithersburg, MD (June 8, 2021) - miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced the hiring of Fu-An Kang, Ph.D. to serve as its Vice President of Research. Dr. Kang joins miRecule after...
Integrated genomic and functional microRNA analysis identifies miR-30-5p as a tumor suppressor and potential therapeutic nanomedicine in head and neck cancer – Clinical Cancer Research
miRecule closes Seed Round at the second annual BioHealth Capital Region Investment Conference – BioBuzz
miRecule, Inc., is developing a novel treatment for FSHD – FSHD Society
Antisense Oligonucleotide-Antibody Conjugates to Treat FSHD – Friends of FSH Research
USM Maryland Momentum Fund Invests $250,000 in $3.5M Seed Round of miRecule Inc. – USM Momentum Fund